TRAXENS
19.9.2018 16:02:11 CEST | Business Wire | Press release
TRAXENS today announced that ERCI Eurail Clusters has named TRAXENS DIGITAL FREIGHT TRAIN, Europe's first Freight Train to use an innovative IoT-based system allowing digitalization of operations, the winner of their « Coup de Cœur » Innovation Award. The prize has been given to the company at the InnoTrans 2018 tradeshow in Berlin.
Initially launched with Fret SNCF, the TRAXENS DIGITAL FREIGHT TRAIN solution is based on smart devices capable of communicating with each other using wireless digital network. TRAXENS solution goes beyond smart wagons to connect the entire train offering new high-value-added services.
Inherited from the Shipping Industry, TRAXENS DIGITAL FREIGHT TRAIN has been designed to work worldwide and manage any type of asset (e.g., Dry or Reefer container, wagon, trailer) which means that rail freight can be connected to the rest of the supplier chain anywhere, to explore and leverage door-to-door multimodal applications.
« This industry recognition is a major milestone for us. We have achieved to design and implement with our partner SNCF Logistics such a solution in a two-year timeframe, which has never been experienced in the industry. We are looking forward to extending the solution worldwide, said Florence Delalande, Rail Business Unit Director at TRAXENS.
Dirk-Ulrich Krüger, Spokesperson of the European Railway Clusters Initiative, comments: « We are thrilled to recognize next-generation innovation in the railway industry, and that’s why TRAXENS has earned this award from ERCI Eurail Clusters. Some of the best solutions, come from these kinds of forward-thinking players who think outside of the box. »
The DIGITAL FREIGHT TRAIN innovation enables the stakeholders of the railway ecosystem to share benefits and costs:
Railway undertakings optimise their wagon fleet and streamline operations.
Shippers geolocate their shipments in real-time anywhere around the world and receive alerts when their shipment arrives at key locations
Wagon keepers can use preventive and predictive maintenance based on hard facts (accurate mileage tracking, information on abnormal shocks, brake and axle monitoring).
Customized services are possible: remote control, door opening, temperature and humidity monitoring.
About ERCI Innovation Awards
The ERCI Innovation Awards recognize companies from ERCI partner clusters that have successfully introduced innovative products or solutions to the market. The prize is initiated by the European Railway Clusters Initiative (ERCI).
The categories of the ERCI Innovation Awards are:
- “Best Large Enterprise”
- “Best SME”
- “Coup de Cœur” special jury prize
The term of the award is annually. Hosting of the award ceremony rotates among the ERCI members. The 2018 awarding ceremony was hosted by the Cluster Transport, Mobility and Logistics Berlin-Brandenburg at InnoTrans 2018 on Wednesday, 19 September 2018.
The awarding ceremony, which took place at the Berlin-Brandenburg joint booth in the CityCube, hall B, on Wednesday, 19 September 2018, was organised by the ERCI partner Cluster Transport, Mobility and Logistics in Berlin and Brandenburg with support from Berlin Partner of Business and Technology. The ERCI Innovation Awards Ceremony took place for the fourth time in 2018:
About ERCI
The European Railway Clusters Initiative was founded in 2010 with the signature of the cooperation treaty on InnoTrans 2010. Member clusters of ERCI are:
- I-Trans competitiveness cluster (Famars, France)
- BTS Rail Saxony (Dresden, Germany)
- Cluster Mobilität, Verkehr und Logistik Berlin-Brandenburg, c/o Berlin Partner for Business and Technology (Berlin, Germany)
- CNA Cluster Bahntechnik Bayern (Nuremberg, Germany)
- DITECFER (Pistoia, Italy)
- Inno-Pro (Karup, Denmark)
- Järnvägsklustret (Västeras, Sweden)
- Logistics in Wallonia (Grace-Hollogne, Belgium)
- The Rail Alliance (Birmingham, UK)
- Railgrup (Barcelona, Spain)
- Southern Railway Cluster (Katowice, Poland)
The 11 partner clusters represent more than 1,000 companies from railway industry from all over Europe. ERCI aims aims to promote innovation and the development of new business opportunities as a means of sustainably bolstering competitiveness within the European railway industry. ERCI fosters collaboration between industry and research, initiates innovation projects and organises B2B meetings and workshops. This also includes the promotion of good visibility and networking at EU level.
Projects with participation of ERCI partner clusters include
-
PERES (Promoting European Rail Excellence outSide EU), an ESCP 4i
partnership under the roof of the European Cluster Collaboration
Platform (ESCP).
More information: http://www.peresinfo.com/ - RECORD (Regions in Europe Coordinate and Optimize innovation and competitiveness policy instruments towards improving the sustainability of transport – study case of SMEs in the railway sector). More information: https://www.interregeurope.eu/record/
About TRAXENS :
TRAXENS delivers the world's most exhaustive, precise and timely information about containers in transit anywhere in the world using breakthrough technology and Big Data techniques. This information provides all stakeholders in multi-modal transport the opportunity to improve costs, optimize investment, and offer premium services.
For more information: www.traxens.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180919005029/en/
Contact:
Press Contact: TRAXENS Geraldine Sauniere, Tel: +33-6-95-91-58-99 Director of Communications g.sauniere@traxens.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom